Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
14/05/2024 | 16:00 | GlobeNewswire Inc. | Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting | NASDAQ:KYMR | Kymera Therapeutics Inc |
08/05/2024 | 13:00 | GlobeNewswire Inc. | Kymera Therapeutics to Participate in Upcoming May Investor Conferences | NASDAQ:KYMR | Kymera Therapeutics Inc |
02/05/2024 | 13:00 | GlobeNewswire Inc. | Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update | NASDAQ:KYMR | Kymera Therapeutics Inc |
25/04/2024 | 13:00 | GlobeNewswire Inc. | Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2 | NASDAQ:KYMR | Kymera Therapeutics Inc |
08/04/2024 | 13:00 | GlobeNewswire Inc. | Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting | NASDAQ:KYMR | Kymera Therapeutics Inc |
08/03/2024 | 16:00 | GlobeNewswire Inc. | Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting | NASDAQ:KYMR | Kymera Therapeutics Inc |
05/03/2024 | 00:21 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:KYMR | Kymera Therapeutics Inc |
04/03/2024 | 23:50 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:KYMR | Kymera Therapeutics Inc |
28/02/2024 | 13:00 | GlobeNewswire Inc. | Kymera Therapeutics to Participate in Upcoming March Investor Conferences | NASDAQ:KYMR | Kymera Therapeutics Inc |
22/02/2024 | 13:32 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:KYMR | Kymera Therapeutics Inc |
22/02/2024 | 13:10 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:KYMR | Kymera Therapeutics Inc |
22/02/2024 | 13:00 | GlobeNewswire Inc. | Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update | NASDAQ:KYMR | Kymera Therapeutics Inc |
15/02/2024 | 13:00 | GlobeNewswire Inc. | Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22 | NASDAQ:KYMR | Kymera Therapeutics Inc |
31/01/2024 | 13:00 | GlobeNewswire Inc. | Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference | NASDAQ:KYMR | Kymera Therapeutics Inc |
09/01/2024 | 15:17 | GlobeNewswire Inc. | Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs | NASDAQ:KYMR | Kymera Therapeutics Inc |
09/01/2024 | 15:15 | GlobeNewswire Inc. | Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares | NASDAQ:KYMR | Kymera Therapeutics Inc |
05/01/2024 | 22:02 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:KYMR | Kymera Therapeutics Inc |
05/01/2024 | 12:00 | GlobeNewswire Inc. | Kymera Therapeutics Announces Pricing of $275 Million Public Offering | NASDAQ:KYMR | Kymera Therapeutics Inc |
04/01/2024 | 22:01 | GlobeNewswire Inc. | Kymera Therapeutics Announces Proposed Public Offering | NASDAQ:KYMR | Kymera Therapeutics Inc |
04/01/2024 | 13:00 | GlobeNewswire Inc. | R&D Day Highlights Kymera’s Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases | NASDAQ:KYMR | Kymera Therapeutics Inc |
02/01/2024 | 13:00 | GlobeNewswire Inc. | Kymera Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 | NASDAQ:KYMR | Kymera Therapeutics Inc |
13/12/2023 | 13:00 | GlobeNewswire Inc. | Kymera Therapeutics to Host Virtual Immunology R&D Day on January 4 | NASDAQ:KYMR | Kymera Therapeutics Inc |
11/12/2023 | 03:00 | GlobeNewswire Inc. | Kymera Therapeutics Presents Interim Results from STAT3 Degrader Phase 1 Clinical Trial at American Society of Hematology Annual Meeting | NASDAQ:KYMR | Kymera Therapeutics Inc |
07/12/2023 | 13:00 | GlobeNewswire Inc. | Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi | NASDAQ:KYMR | Kymera Therapeutics Inc |
13/11/2023 | 17:00 | GlobeNewswire Inc. | Kymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-in-Class IRAK4 Degrader, in Nature Medicine | NASDAQ:KYMR | Kymera Therapeutics Inc |
02/11/2023 | 14:00 | GlobeNewswire Inc. | Kymera Therapeutics to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual Meeting | NASDAQ:KYMR | Kymera Therapeutics Inc |
02/11/2023 | 12:15 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:KYMR | Kymera Therapeutics Inc |
02/11/2023 | 12:00 | GlobeNewswire Inc. | Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update | NASDAQ:KYMR | Kymera Therapeutics Inc |
01/11/2023 | 12:00 | GlobeNewswire Inc. | Kymera Therapeutics to Participate in Upcoming November Investor Conferences | NASDAQ:KYMR | Kymera Therapeutics Inc |
27/10/2023 | 13:00 | GlobeNewswire Inc. | Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi | NASDAQ:KYMR | Kymera Therapeutics Inc |